In a cross-sectional study of 240 patients with chronic kidney disease, higher serum BDNF levels and a ...
The US FDA has approved GSK’s Hibsago for chronic hepatitis B, with 19% of trial participants achieving a functional cure.
A computational study identified 368 putative compounds in Guduchyadi Yoga and modeled persistent binding by three selected phytochemicals to AKT1, PPARG and TNF, but did not test therapeutic effects ...
Chronic hepatitis B is a long-term liver infection caused by HBV. Over time, the infection can lead to serious liver disease, including cirrhosis, and increase the risk of liver cancer. Hibsago works ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results